| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6446627 | TEVA BRANDED PHARM | Inhaler dose counter |
Dec, 2017
(6 years ago) | |
| US8006690 | TEVA BRANDED PHARM | Reservoir pressure system for medicament inhaler |
Jun, 2021
(2 years ago) | |
| US6748947 | TEVA BRANDED PHARM | De-agglomerator for breath-actuated dry powder inhaler |
Jun, 2021
(2 years ago) | |
| US6701917 | TEVA BRANDED PHARM | Dose counter for medicament inhaler |
Jun, 2021
(2 years ago) | |
| US6718972 | TEVA BRANDED PHARM | Dose metering system for medicament inhaler |
Jun, 2021
(2 years ago) | |
| US6871646 | TEVA BRANDED PHARM | De-agglomerator for breath-actuated dry powder inhaler |
Jun, 2021
(2 years ago) | |
| US7540282 | TEVA BRANDED PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(11 months ago) | |
| US9463288 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 15 days from now) | |
| US10765820 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 15 days from now) | |
| US8651103 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
| US10124131 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US9731087 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US9216260 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(7 years from now) | |
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| US9782550 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US9782551 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
Proair Respiclick is owned by Teva Branded Pharm.
Proair Respiclick contains Albuterol Sulfate.
Proair Respiclick has a total of 18 drug patents out of which 7 drug patents have expired.
Expired drug patents of Proair Respiclick are:
- US6446627
- US8006690
- US6748947
- US6701917
- US6718972
- US6871646
- US7540282
Proair Respiclick was authorised for market use on 21 December, 2018.
Proair Respiclick is available in powder, metered;inhalation dosage forms.
The generics of Proair Respiclick are possible to be released after 28 August, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR RESPICLICK family patents
